Anti-Müllerian Hormone Confirms the Novel Classification of Female Functional Androgenization Including Polycystic Ovary Syndrome

In the 2011 study involving 178 patients with functional androgenization (FA), including polycystic ovary syndrome (PCOS), and a control group of 30 women, Anti-Müllerian hormone (AMH) was found to be significantly higher in FA patients, with levels of 11.1±6.7 ng/ml compared to 3.0±2.0 ng/ml in controls. AMH levels were particularly elevated in groups with ovarian involvement and correlated positively with luteinizing hormone (LH) and testosterone, but not with SHBG, DHEAS, BMI, glucose, or insulin. An AMH level above 9.21 ng/ml had a 90% specificity and 71.2% sensitivity for diagnosing ovarian FA. The study concluded that AMH is a specific marker for ovarian pathology in FA and can be used for FA classification, particularly when vaginal sonographic examination is not possible. The study also suggested that while ovarian reserve may be high in certain FA types, the likelihood of pregnancy in PCOS patients is more related to age than ovarian reserve. The study was supported by MSD/Essex Pharma but maintained independence in its design, evaluation, and publication.